Navigation Links
Vaxart Begins Animal Testing of H1N1 Flu Vaccine Candidate
Date:5/26/2009

SAN FRANCISCO, May 26 /PRNewswire/ -- Vaxart, Inc., a biotechnology company focused on the development of oral vaccines, announced today that the company has created a candidate vaccine for H1N1 influenza (swine flu). On Saturday, May 23, Vaxart began testing for immune responses in animals, just 25 days after initiating the project. The company will compare performance of the research-grade H1N1 vaccine to its successful avian flu vaccine as a first step towards potential human clinical testing.

The company has also begun preparing source material suitable for production of human H1N1 vaccine; an initial batch could be produced by August. However, human testing may not begin until fall or later, due to the need for safety testing in animals.

"Our oral vaccine could provide an important tool for swine flu pandemic preparation, because of the speed with which it could be delivered to groups such as first-line medical personnel," said Sean Tucker, Ph.D., Vaxart vice president of research.

Currently, pandemic flu vaccines are prepared by a slow and inefficient process that requires about six months before the first large amounts of vaccine are available. This process depends on creating an engineered variant of the circulating pandemic influenza strain and growing it in eggs. An advantage of Vaxart's approach is that it does not require culturing the flu virus in eggs; company scientists make a new vaccine by inserting a small piece of DNA matching the pandemic strain into Vaxart's pre-constructed vector. Vaxart's vector grows quickly and reproducibly in cell culture using a standard process.

Vaxart vaccines are novel in several ways, including the fact that they can be taken orally (i.e., by swallowing a capsule). In addition, the product is stable enough to be distributed without refrigeration. In an emergency, an approved Vaxart vaccine could be supplied by mail, rather than risking the spread of disease caused by individuals visiting clinics to receive injections. Vaxart's approach has important advantages over other platform technologies under development. Vaxart has shown that prior exposure to their platform vector does not impact the performance of later vaccinations. The company has previously demonstrated that its avian flu prototype vaccine has the ability to protect animals from lethal exposure to the pandemic strain.

"We look forward to continuing our work with government authorities and funding agencies to pursue this very promising vaccine for H1N1 influenza," said Mark Backer, Ph.D., Vaxart CEO.

About Vaxart

Vaxart (www.vaxart.com) is a privately held biotechnology company focused on the development of oral vaccines. Vaxart's proprietary approach is ideally suited for modular creation of vaccines, enabling the company to reduce development risk. Vaxart intends to apply its platform to develop a first-in-class vaccine for pandemic influenza, as well as creating oral alternatives to current vaccines such as annual influenza and HPV. The company expects to begin clinical testing of its pandemic flu vaccine in 2009.

    Contact: Michele Parisi
             for Vaxart
             925/429-1850
             ir-pr@vaxart.com


'/>"/>
SOURCE Vaxart, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Vaxart Demonstrates Efficacy of Oral Avian Flu Vaccine in Preclinical Studies
2. DOV Pharmaceutical, Inc. Begins Trading on OTC Bulletin Board
3. Genzyme Begins Major Expansion of Boston Manufacturing Facility
4. Medical Services Begins Working With United States Companies for Distribution of Its Products
5. Phlo Affiliate Begins Roll Out to Metropolitan New York City Account Base
6. Care to Care Begins Providing Radiology Benefit Management Services to Touchstone Health
7. SPO Medical Begins Shipping PulseOx 6000(TM) and PulseOx 6100(TM)
8. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
9. Ohio Task Force Begins Mission of Creating a New 21st Century Industry
10. Thomson Scientific Begins Expansion of Web of Science
11. Nikon Instruments Begins Direct Sales and Technical Support in Southern California and Rocky Mountain Territories
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... ... March 22, 2017 , ... The Society for Immunotherapy of ... outlined in the Administration’s recently published fiscal year 2018 budget request. , ... Health (NIH) by $5.8 billion or roughly 20% of its total budget. If applied ...
(Date:3/22/2017)...  RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage ... unmet medical needs, today announced Alexey Eliseev ... at the 5th Annual Cancer BioPartnering & Investment ... present to and meet with thought leaders from ... as well as institutional investors. This event will ...
(Date:3/20/2017)... ... March 20, 2017 , ... ... and biotech companies, recently announced it will debut a brand new pressure vessel, ... The intelliVessel is controlled by a touch screen panel and features other revolutionary ...
(Date:3/20/2017)... ... 2017 , ... The fourth annual Hackaday Prize , which aims to ... on peoples’ lives, launches today. Sponsored by Digi-Key and Microchip , ... in cash prizes to engineers, inventors and tinkerers who “build something that matters.” , ...
Breaking Biology Technology:
(Date:2/21/2017)... , February 21, 2017 Der ... US-Dollar wachsen. Nach einem Gespräch mit mehr als 50 Vertretern ... Hindernisse zu überwinden gilt, um diese Prognose zu realisieren. ... ... die Mobilisierung der finanziellen Mittel für die Biobank, die ...
(Date:2/13/2017)... 2017 Former 9/11 Commission border counsel and ... Janice Kephart of Identity Strategy Partners, LLP, today ... "Executive Order: Protecting the Nation From Foreign Terrorist ... "As President Trump,s ,Travel Ban, Executive Order gains ... banned the travel ban, it is important that our ...
(Date:2/8/2017)... (NASDAQ: AWRE ), a leading supplier of biometrics ... and year ended December 31, 2016. Revenue ... to $6.9 million in the same quarter last year. Operating ... compared to $2.6 million in the fourth quarter of 2015. ... million, or $0.02 per diluted share, which compares to $1.8 ...
Breaking Biology News(10 mins):